파인메딕스
Financials
Valuation Metrics
파인메딕스's Market Cap is ₩264B. At end of 2025 it was ₩422B. Ranked #2143 of 2,436 in KR market (top 88%), #1379 of 1,649 on KOSDAQ (top 84%), #89 of 96 in Health Care Equipment & Services (top 93%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 26.41B KRW | KR#2,143/2,436 Sec#89/96 |
| Revenue | 9.86B KRW | KR#2,290/2,436 Sec#83/96 |
| Net Income | -1.78B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 24.49B KRW | KR#2,352/2,436 Sec#92/96 |
| Net Assets | 18.31B KRW | KR#2,299/2,436 Sec#90/96 |
| Employees | 74 | KR#1,829/2,436 Sec#71/96 |
| Value | ||
| P/B | 1.44x | KR#1,760/2,436 Sec#56/96 |
| P/S | 2.68x | KR#1,970/2,436 Sec#61/96 |
| FCF Yield | -13.20% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -9.75% | KR#1,894/2,436 Sec#63/96 |
| ROA | -7.29% | KR#1,985/2,436 Sec#66/96 |
| Op. Margin | -25.16% | KR#2,161/2,436 Sec#72/96 |
| Revenue Growth | 17.54% | KR#689/2,436 Sec#30/96 |
| Financial Health | ||
| Debt Ratio | 133.76% | KR#923/2,436 Sec#41/96 |
| Total Debt | 2.99B KRW | KR#1,864/2,436 Sec#68/96 |
| FCF | -3.49B KRW | KR#1,424/2,436 Sec#49/96 |
| Cash | 4.64B KRW | KR#2,023/2,436 Sec#72/96 |
| Current Ratio | 5.78x | KR#238/2,436 Sec#15/96 |
| Performance | ||
| 1Y Return | -37.73% | KR#1,783/2,436 Sec#61/96 |
| 1M Return | 2.85% | KR#613/2,436 Sec#32/96 |
| From 52W High | -50.73% | KR#1,229/2,436 Sec#47/96 |
| 1Y MDD | -57.61% | KR#1,284/2,436 Sec#44/96 |
| Trading | ||
| Volume | 11,625 shares | KR#2,072/2,436 Sec#86/96 |
| Foreign Own. | 1.17% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -317 KRW | KR—/2,436 Sec—/96 |
| BPS | 3,372 KRW | KR#1,732/2,436 Sec#47/96 |
Company Info
Fine Medic, established in 2009, is a specialized manufacturer of advanced digestive endoscopic procedure instruments, listed on KOSDAQ in 2024. The company has localized endoscopic incision knives, snares, and injectors, securing over 20% domestic market share and expanding sales in Japan, Europe, and the U.S. based on CE and FDA certifications. Leveraging the CEO's more than 20 years of clinical experience, Fine Medic has established a unified development system to promptly productize the needs of the medical field. It is headquartered in Dong-gu, Daegu Metropolitan City.